Premier Consulting’s Post

Many companies want to optimize their drug substance production, but they worry about contamination and product loss. When you’re looking for a CMDO, here are four strategies to maximize drug substance utilization: https://bit.ly/3Xu5nvN #pharmamfg #contractmfg

Many companies want to optimize their drug substance production, but they worry about contamination and product loss. When you’re looking for a CMDO, here are four strategies to maximize drug substance utilization: https://bit.ly/3ybxhlS #pharmamfg #contractmfg

Many companies want to optimize their drug substance production, but they worry about contamination and product loss. When you’re looking for a CMDO, here are four strategies to maximize drug substance utilization: https://bit.ly/3AhPizU #pharmamfg #contractmfg

Many companies want to optimize their drug substance production, but they worry about contamination and product loss. When you’re looking for a CMDO, here are four strategies to maximize drug substance utilization: https://bit.ly/3Yuf3Xd #pharmamfg #contractmfg

Many companies want to optimize their drug substance production, but they worry about contamination and product loss. When you’re looking for a CMDO, here are four strategies to maximize drug substance utilization: https://bit.ly/3WNAhhP #pharmamfg #contractmfg

"Evolving Paradigms in Drug Regulation: Traditional Approaches vs. Modern Innovations". #ComplexRegulations #ManualProcesses #TraditionalTrials #LimitedTech #EnvironmentalGaps #UnifiedSubmissions #MasterProtocols #AIinClinicalTrials #TechDrivenRegulation #ComprehensiveSafety #DrugRegulationRevolution #PharmaInnovation #ClinicalTrials2024 #FutureOfPharma #SustainablePharma #PharmaRevolution #NextGenRegulation #ClinicalInnovation #SmartPharma #RegulatoryExcellence #StreamlinedRegulation #InnovativeProtocols #AIEnhancedTrials #DigitalHealth #EcoFriendlyPharma

Many companies want to optimize their drug substance production, but they worry about contamination and product loss. When you’re looking for a CMDO, here are four strategies to maximize drug substance utilization: https://bit.ly/4dmRzaS #pharmamfg #contractmfg

We just released our July Pipeline Report! 🚀✨ This comprehensive report offers insights into recent drug approvals, products on our radar, and more! 📊🔍Get your hands on the full report: https://bit.ly/4frsUEg #pipelinereport #newmedications #fdaapproved #specialtypharmacy

The IQVIA Pharma Deals Half Year Review of 2024 reveals important trends in the pharmaceutical sector's mergers, acquisitions (M&A), and licensing activities. Although the number of M&A deals dropped by 20% compared to the first half of 2023, the total value of these deals increased significantly. This shows that big pharmaceutical companies, like Johnson & Johnson, Merck & Co., and Gilead Sciences, are focusing on larger, more strategic acquisitions, especially in the areas of oncology and immunology. Licensing deals also saw a change. While the number of deals fell by 24%, the overall value went up by 22%. This suggests that companies are more interested in securing high-value, later-stage products rather than a large number of early-stage assets. Oncology remained the top focus for deals, driven by advances in immuno-oncology and new treatments like radiopharmaceuticals. Looking ahead, the report predicts that deal-making will continue, particularly as many major drug patents are set to expire. This will push companies to look for new, innovative therapies through acquisitions and partnerships. Although regulatory issues may limit some large deals, targeted acquisitions and licensing agreements will likely remain a key strategy for future growth. For more detailed insights, IQVIA provides a comprehensive analysis on this topic. #pharma #pharmadevelopment #pharmadeals #strategy #pharmastrategy #pharmalicensing #pharmaceuticalstrategy

I studied this course. It was useful to catch the general concept up and understand current situation of drug research based on the regulation on FDA and EMA .